From antiangiogenesis to hypoxia: Current research and future directions

Cancer Management and Research

Volumn 3, Issue 1, 2011, Pages 9-16

  Rice, Christopher ^a   Eric Huang, L ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Antiangiogenesis; Genetic alteration; Hypoxia; Tumor progression

Indexed keywords

ALPHA2A INTERFERON; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; BASIC FIBROBLAST GROWTH FACTOR; BEVACIZUMAB; ENDOSTATIN; FLUOROURACIL; FOLINIC ACID; FUMAGILLOL CHLOROACETYLCARBAMATE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IRINOTECAN; MELPHALAN; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; OXALIPLATIN; PLACEBO; PREDNISOLONE; SEMAXANIB; THALIDOMIDE; TOPOTECAN; VASCULOTROPIN; VATALANIB;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER GROWTH; COLORECTAL CANCER; DISEASE MODEL; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TREATMENT FAILURE; GLIOMA; HEAD AND NECK CANCER; HEAD AND NECK CARCINOMA; HUMAN; HYPOXIA; KIDNEY CANCER; KIDNEY CARCINOMA; MELANOMA; MULTIPLE MYELOMA; NEOVASCULARIZATION (PATHOLOGY); NEUROENDOCRINE TUMOR; NONHUMAN; OVERALL SURVIVAL; PROSTATE CANCER; REVIEW; SOFT TISSUE SARCOMA; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; TUMOR VASCULARIZATION;

EID: 79251476288     PISSN: None     EISSN: 11791322     Source Type: Book Series    
DOI: 10.2147/CMR.S14812     Document Type: Review

References (78)

1. Ide AG, Baker NH, Warren SL. Vascularization of the Brown-Pearce rabbit epithelioma transplant as seen in the transparent ear chamber. AJR Am J Roentgenol. 1939; 42:891-899.
2. Algire GH, Chalkley HW. Vascular reactions of normal and malignant tissues in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants. J Natl Cancer Inst. 1945; 6:73-85.
3. Greene HS. Heterologous transplantation of mammalian tumors: I. The transfer of rabbit tumors to alien species. J Exp Med. 1941; 73(4): 461-474.
4. Folkman J, Cole P, Zimmerman S. Tumor behavior in isolated perfused organs: in vitro growth and metastases of biopsy material in rabbit thyroid and canine intestinal segment. Ann Surg. 1966; 164(3):491-502.
5. Gimbrone MA, Aster RH, Cotran RS, Corkery J, Jandl JH, Folkman J. Preservation of vascular integrity in organs perfused in vitro with a platelet-rich medium. Nature. 1969; 222(5188):33-36.
6. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971; 285(21):1182-1186.
7. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 1997; 390(6658):404-407.
8. Folkman J. Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med. 1995; 333(26):1757-1763.
9. Shing Y, Folkman J, Sullivan R, Butterfeld C, Murray J, Klagsbrun M. Heparin affnity: purification of a tumor-derived capillary endothelial cell growth factor. Science. 1984; 223(4642):1296-1299.
10. Folkman J, Klagsbrun M. Angiogenic factors. Science. 1987; 235(4787): 442-447.
11. Keck PJ, Hauser SD, Krivi G, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science. 1989; 246(4935): 1309-1312.
12. Leung DW, Cachianes G, Kuang WJ, Goeddel D V, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989; 246(4935):1306-1309.
13. Alon T, Hemo I, Itin A, Pe'er J, Stone J, Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med. 1995; 1(10):1024-1028.
14. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev. 1997; 18(1):4-25.
15. Davis S, Aldrich TH, Jones P F, et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell. 1996; 87(7):1161-1169.
16. Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science. 1999; 284(5422):1994-1998.
17. Koch AE, Polverini PJ, Kunkel SL, et al. Interleukin-8 as a macro-phage-derived mediator of angiogenesis. Science. 1992; 258(5089): 1798-1801.
18. Strieter RM, Kunkel SL, Elner VM, et al. Interleukin-8. A corneal factor that induces neovascularization. Am J Pathol. 1992; 141(6): 1279-1284.
19. Kandel J, Bossy-Wetzel E, Radvanyi F, Klagsbrun M, Folkman J, Hanahan D. Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell. 1991; 66(6):1095-1104.
20. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996; 86(3):353-364.
21. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994; 91(9): 4082-4085.
22. Tseng JE, Glisson BS, Khuri FR, et al. Phase II study of the antian-giogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer. 2001; 92(9):2364-2373.
23. Figg WD, Dahut W, Duray P, et al. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res. 2001; 7(7):1888-1893.
24. Stadler WM, Kuzel T, Shapiro C, Sosman J, Clark J, Vogelzang NJ. Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma. J Clin Oncol. 1999; 17(8):2541-2545.
25. Logothetis CJ, Wu KK, Finn LD, et al. Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer. Clin Cancer Res. 2001; 7(5):1198-1203.
26. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angio-genesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 1994; 79(2):315-328.
27. Beerepoot LV, Witteveen EO, Groenewegen G, et al. Recombinant human angiostatin by twice-daily subcutaneous injection in advanced cancer: a pharmacokinetic and long-term safety study. Clin Cancer Res. 2003; 9(11):4025-4033.
28. Soff GA, Wang H, Cundiff DL, et al. In vivo generation of angiosta-tin isoforms by administration of a plasminogen activator and a free sulfhydryl donor: a phase I study of an angiostatic cocktail of tissue plasminogen activator and mesna. Clin Cancer Res. 2005; 11(17): 6218-6225.
29. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997; 88(2): 277-285.
30. Herbst RS, Hess KR, Tran HT, et al. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol. 2002; 20(18):3792-3803.
31. Kulke MH, Bergsland EK, Ryan D P, et al. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol. 2006; 24(22):3555-3561.
32. Markovic SN, Suman VJ, Rao RA, et al. A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma. Am J Clin Oncol. 2007; 30(3):303-309.
33. Baker LH, Rowinsky EK, Mendelson D, et al. Randomized, phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcoma. J Clin Oncol. 2008; 26(34):5583-5588.
34. Fury MG, Zahalsky A, Wong R, et al. A phase II study of SU5416 in patients with advanced or recurrent head and neck cancers. Invest New Drugs. 2007; 25(2):165-172.
35. Roboz GJ, Giles FJ, List A F, et al. Phase 1study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Leukemia. 2006; 20(6):952-957.
36. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of beva-cizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003; 349(5):427-434.
37. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus iri-notecan, fuorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350(23):2335-2342.
38. van Cutsem E, Vervenne WL, Bennouna J, et al. Phase III trial of beva-cizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol. 2009; 27(13):2231-2237.
39. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as frst-line therapy in meta-static colorectal cancer: a randomized phase III study. J Clin Oncol. 2008; 26(12):2013-2019.
40. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007; 357(26):2666-2676.
41. Escudier B, Bellmunt J, Negrier S, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): fnal analysis of overall survival. J Clin Oncol. 2010; 28(13):2144-2150.
42. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fuorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007; 25(12):1539-1544.
43. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006; 355(24):2542-2550.
44. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. Combined analysis of efficacy: the addition of bevacizumab to fuorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol. 2005; 23(16):3706-3712.
45. Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet. 2007; 370(9594):1209-1218.
46. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalido-mide in refractory multiple myeloma. N Engl J Med. 1999; 341(21): 1565-1571.
47. Lee CG, Heijn M, di Tomaso E, et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 2000; 60(19):5565-5570.
48. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005; 307(5706):58-62.
49. Fukumura D, Duda DG, Munn LL, Jain RK. Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models. Microcirculation. 2010; 17(3):206-225.
50. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell. 2005; 8(4):299-309.
51. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008; 8(8):579-591.
52. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003; 3(10):721-732.
53. Elson DA, Thurston G, Huang LE, et al. Induction of hypervascu-larity without leakage or inflammation in transgenic mice overex-pressing hypoxia-inducible factor-1alpha. Genes Dev. 2001; 15(19): 2520-2532.
54. Mazzone M, Dettori D, Leite de Oliveira R, et al. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell. 2009; 136(5):839-851.
55. Lamszus K, Kunkel P, Westphal M. Invasion as limitation to anti-angiogenic glioma therapy. Acta Neurochir Suppl. 2003; 88:169-177.
56. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008; 8(8):592-603.
57. Lucio-Eterovic AK, Piao Y, de Groot JF. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Clin Cancer Res. 2009; 15(14):4589-4599.
58. Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009; 15(3):220-231.
59. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009; 15(3): 232-239.
60. Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant gliomas: effcacy, toxicity, and patterns of recurrence. Neurolog y. 2008; 70(10):779-787.
61. Verhoeff JJ, van Tellingen O, Claes A, et al. Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme. BMC Cancer. 2009; 9:444.
62. Bertout JA, Patel SA, Simon MC. The impact of O2 availability on human cancer. Nat Rev Cancer. 2008; 8(12):967-975.
63. Huang LE, Bunn HF. Hypoxia-inducible factor and its biomedical relevance. J Biol Chem. 2003; 278(22):19575-19578.
64. Kaelin WG Jr, Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell. 2008; 30(4): 393-402.
65. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer. 2002; 2(1):38-47.
66. Huang LE, Bindra RS, Glazer PM, Harris AL. Hypoxia-induced genetic instability - a calculated mechanism underlying tumor progression. J Mol Med. 2007; 85(2):139-148.
67. Bristow RG, Hill R P. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer. 2008; 8(3):180-192.
68. Huang LE. Carrot and stick: HIF-alpha engages c-Myc in hypoxic adaptation. Cell Death Differ. 2008(4); 15:672-677.
69. Gordan JD, Lal P, Dondeti VR, et al. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-defcient clear cell renal carcinoma. Cancer Cell. 2008; 14(6):435-446.
70. Koshiji M, To KK, Hammer S, et al. HIF-1alpha induces genetic instability by transcriptionally downregulating MutSalpha expression. Mol Cell. 2005; 17(6):793-803.
71. To KK, Sedelnikova OA, Samons M, Bonner WM, Huang LE. The phos-phorylation status of PAS-B distinguishes HIF-1alpha from HIF-2alpha in NBS1 repression. EMBO J. 2006; 25(20):4784-4794.
72. Koshiji M, Kageyama Y, Pete EA, Horikawa I, Barrett JC, Huang LE. HIF-1alpha induces cell cycle arrest by functionally counteracting Myc. EMBO J. 2004; 23(9):1949-1956.
73. Yoo YG, Christensen J, Huang LE. HIF-1α confers aggressive malignant traits on human tumor cells independent of its canonical transcriptional function. Cancer Res. (In press).
74. To KK, Koshiji M, Hammer S, Huang LE. Genetic instability: the dark side of the hypoxic response. Cell Cycle. 2005; 4(7):881-882.
75. Pietras K, Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose 'chemo-switch' regimen is antiangiogenic, producing objective responses and survival beneft in a mouse model of cancer. J Clin Oncol. 2005; 23(5):939-952.
76. Melillo G. Inhibiting hypoxia-inducible factor 1 for cancer therapy. Mol Cancer Res. 2006; 4(9):601-605.
77. Rapisarda A, Uranchimeg B, Sordet O, Pommier Y, Shoemaker RH, Melillo G. Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res. 2004; 64(4):1475-1482.
78. Rapisarda A, Hollingshead M, Uranchimeg B, et al. Increased antitu-mor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Mol Cancer Ther. 2009; 8(7):1867-1877.